Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-14
DOI
10.3389/fonc.2021.683570
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer
- (2021) Tien-Hua Chen et al. Journal of the Chinese Medical Association
- Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
- (2020) X. Zhao et al. ANNALS OF ONCOLOGY
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
- (2019) Rodrigo Barbosa de Aguiar et al. Frontiers in Immunology
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- (2019) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer
- (2018) Peter H. Ahn et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
- (2018) Edwin P. Hui et al. CLINICAL CANCER RESEARCH
- Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
- (2018) Douglas Adkins et al. LANCET ONCOLOGY
- Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma
- (2018) Min Kang et al. MEDICINE
- Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
- (2018) Yuhei Kogata et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
- (2017) Ziad Hussein et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Sorafenib: A Review in Hepatocellular Carcinoma
- (2017) Gillian M. Keating Targeted Oncology
- Sunitinib in the Treatment of Thyroid Cancer
- (2017) Silvia Martina Ferrari et al. CURRENT MEDICINAL CHEMISTRY
- Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
- (2016) A. Argiris et al. ANNALS OF ONCOLOGY
- Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
- (2016) Zhexuan Lin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
- (2016) Sai Ge et al. Oncology Letters
- Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
- (2015) Amit Walia et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
- (2015) Gemma Gatta et al. EUROPEAN JOURNAL OF CANCER
- Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
- (2015) Vasiliki A. Papadimitrakopoulou et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma
- (2015) Matthew G. Fury et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
- (2015) Yassine Lalami et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion
- (2015) Matthew J. Nyflot et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
- (2015) Paul L. Swiecicki et al. INVESTIGATIONAL NEW DRUGS
- Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- (2015) Assuntina G. Sacco et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis in head and neck cancer
- (2015) Maria Vassilakopoulou et al. ORAL ONCOLOGY
- A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) Jill Gilbert et al. ORAL ONCOLOGY
- Selective use of vandetanib in the treatment of thyroid cancer
- (2015) Alessandro Antonelli et al. Drug Design Development and Therapy
- Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck
- (2014) Min Yao et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma
- (2014) Wen Ye et al. MOLECULAR THERAPY
- A Phase II Trial of Endostar Combined With Gemcitabine and Cisplatin Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NCT01612286)
- (2014) Ting Jin et al. ONCOLOGY RESEARCH
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
- (2013) Sewanti Limaye et al. ORAL ONCOLOGY
- Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†
- (2012) C. Xue et al. ANNALS OF ONCOLOGY
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
- (2012) A. Argiris et al. ANNALS OF ONCOLOGY
- A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
- (2012) Matthew G. Fury et al. CANCER
- Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
- (2012) David S. Yoo et al. CLINICAL CANCER RESEARCH
- Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-β1 (TGF-β1)
- (2012) M. Victoria Recouvreux et al. ENDOCRINOLOGY
- Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
- (2012) Tanguy Seiwert et al. INVESTIGATIONAL NEW DRUGS
- Enhancement of radiation response with bevacizumab
- (2012) Tien Hoang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
- (2011) E. P. Hui et al. ANNALS OF ONCOLOGY
- A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
- (2011) J. K. Salama et al. ANNALS OF ONCOLOGY
- E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma
- (2011) Z Adhim et al. CANCER GENE THERAPY
- Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck
- (2011) John D. Hainsworth et al. CANCER JOURNAL
- A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
- (2011) Wan-Teck Lim et al. CLINICAL CANCER RESEARCH
- Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
- (2011) Nancy Y Lee et al. LANCET ONCOLOGY
- Angiogenesis in Head and Neck Cancer: A Review of the Literature
- (2011) Codecà Carla et al. Journal of Oncology
- Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
- (2010) Stephen K. Williamson et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
- (2009) George Fountzilas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of sunitinib malate in head and neck squamous cell carcinoma
- (2009) Nicholas W. Choong et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
- (2009) Jean-Pascal H. Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Axitinib for renal cell carcinoma
- (2008) Guru Sonpavde et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Targeting Angiogenesis in Head and Neck Cancer
- (2008) Tanguy Y. Seiwert et al. SEMINARS IN ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started